(1S,2s)-boc-2-氨基环戊烷羧酸 | 143679-80-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 环羧酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1S,2s)-boc-2-氨基环戊烷羧酸
• 中文别名: (1S,2S)-2-[(叔丁氧羰基)氨基]环戊烷羧酸；(1S,2S)-2-叔丁氧羰氨基-1-环戊烷羧酸
• 英文名称: (1S,2S)-2-((tert-butoxycarbonyl)amino)cyclopentanecarboxylic acid
• 英文别名: (1S,2S)-2-((tert-butoxycarbonyl)amino)cyclopentane-1-carboxylic acid；(1S,2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentane-1-carboxylic acid
• CAS: 143679-80-5
• 化学式: C₁₁H₁₉NO₄
• 分子量: 229.276
• InChiKey: BUEPEVBYNBQNED-YUMQZZPRSA-N

物化性质

• 密度：
  1.15

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  29225090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (1S,2S)-Boc-2-aminocyclopentane carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (1S,2S)-Boc-2-aminocyclopentane carboxylic acid
CAS number: 143679-80-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H19NO4
Molecular weight: 229.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

(1S,2S)-2-[(叔丁氧羰基)氨基]环戊烷羧酸是一种羧酸类有机化合物，可作为有机合成中的重要中间体。

反应信息

• 作为反应物：
  描述：

  (1S,2s)-boc-2-氨基环戊烷羧酸 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 以23.0 g的产率得到tert-butyl ((1S,2S)-2-(hydroxymethyl)cyclopentyl)carbamate
  参考文献：
  名称：

  [EN] OREXIN 1 RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE 1

  摘要：

  本公开涉及公式（I）的新化合物及其盐，其中W；X；Y；Z；R1；R2；R3和R4在此处定义，并其在治疗、预防、改善、控制或减少与促进素受体相关的神经系统或精神障碍的风险中的用途。

  公开号：

  WO2020120994A1
• 作为产物：
  描述：

  (1S)-trans-2-azidocyclopentanecarboxylic acid ethyl ester 在 palladium on activated charcoal lithium hydroxide 、 氢气 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 (1S,2s)-boc-2-氨基环戊烷羧酸
  参考文献：
  名称：

  Analogs of Ac-CCK-7 incorporating dipeptide mimics in place of Met28-Gly29

  摘要：

  A series of analogs of Ac-CCK-7 [Ac-Tyr(SO3H)-Met28-Gly29-Trp-Met-Asp-Phe-NH2, (1)] Were prepared in which the Met28-Gly29 dipeptide was replaced by omega-aminoalkanoic acids. Compounds were assessed in binding assays using homogenated rat pancreatic membranes and bovine striatum as the source of CCK-A and CCK-B receptors, respectively, and for anorectic activity after intraperitoneal administration to rats. The analog incorporating 4-aminobutanoic acid (5) was only 8 times less potent than 1 in the pancreatic binding assay, was more potent in the striatal binding assay, and was more potent than 1 in reducing food intake in rats. Using a bioactive cyclic analog of Ac-CCK-7 as a template, several rigid spacers were designed and tested as substitutes for the Met28-Gly29 dipeptide. The analogs incorporating 3-aminobenzoic acid (20) and (1S)-trans-2-aminocyclopentanecarboxylic acid (26) proved highly effective in the binding assays and as anorectic agents. We hypothesize that for stimulation of CCK-A receptors, the main function of the N-terminal tripeptide of Ac-CCK-7 is to orient the tyrosine sulfate with respect to Trp30 and that the bioactive arrangement of these elements lies among those which are readily available to both 20 and 26. NOESY and distance-constrained molecular dynamics experiments carried out on 20 and 26 identified conformations in which the relative orientation of the tyrosine hydroxide and the alpha-carbon atom of tryptophan were similar, providing the basis for further drug design efforts.

  DOI：

  10.1021/jm00099a005

文献信息

• [EN] THERAPEUTIC AGENTS I<br/>[FR] AGENTS THERAPEUTIQUES I
  申请人：ASTRAZENECA AB

  公开号：WO2005066132A1

  公开（公告）日：2005-07-21

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的化学式(I)，制备这种化合物的方法，它们在治疗肥胖、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫以及相关疾病，以及神经系统疾病如痴呆症、多发性硬化症、帕金森病、亨廷顿舞蹈症、阿尔茨海默病和与疼痛相关的疾病中的应用，以及含有它们的药物组合物。
• [EN] IMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS DE QUERCÉTINE UTILES COMME AGENTS ANTIVIRAUX
  申请人：LUPIN LTD

  公开号：WO2013021344A1

  公开（公告）日：2013-02-14

  Compounds of the general formula (I) their tautomeric forms, their stereoisomers, their analogs, their prodrugs, their isotopes, their N-oxides, their metabolites, their pharmaceutically acceptable salts, polymorphs, solvates, optical isomers, clathrates, co-crystals, combinations with suitable medicament, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as antiviral candidate, more specifically as anti-HCV are disclosed.

  通式（I）的化合物，它们的互变异构体，立体异构体，类似物，前药，同位素，N-氧化物，代谢物，药学上可接受的盐，多型体，溶剂合物，光学异构体，包合物，共晶体，与合适药物的组合，含有它们的药物组合物，上述化合物的制备方法，以及它们作为抗病毒候选药物的用途，更具体地作为抗HCV药物的用途被披露。
• [EN] PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2015013835A1

  公开（公告）日：2015-02-05

  The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

  本发明涉及哌嗪衍生物，包括含有这些衍生物的药物组合物，以及它们在抑制HIV蛋白酶、抑制HIV复制、预防HIV感染、治疗HIV感染以及预防、治疗和延缓艾滋病发病或进展中的用途。
• PENTACYCLIC HETEROCYCLES
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20200283452A1

  公开（公告）日：2020-09-10

  The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof:

  本发明提供了由式(I)至(XVII)表示的化合物或其药学上可接受的盐：
• [EN] OREXIN 1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE 1
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2020120994A1

  公开（公告）日：2020-06-18

  The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

  本公开涉及公式（I）的新化合物及其盐，其中W；X；Y；Z；R1；R2；R3和R4在此处定义，并其在治疗、预防、改善、控制或减少与促进素受体相关的神经系统或精神障碍的风险中的用途。